Unilab

Automata Technologies: $40m fundraise backed by Dimension and A.P. Moller Holding, to expand growing life science lab automation offering

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Technology, Manufacturing, Health, Pharmaceutical, Robotics, Research, Engineering, Science, Machinery, Electronic Design Automation, AstraZeneca, Francis Crick Institute, Unilab, Data collection, Royal Marsden Hospital, Octopus Group, LINQ, Growth, Entrepreneurship, The Royal Marsden NHS Foundation Trust, NHS, HSL, Trust, ChromeOS, Automation, Fine chemical, Video game, Pharmaceutical industry, Cryptocurrency, Automaton

This is happening at the same time as they struggle to find laboratory real estate as well as finding and retaining skilled lab staff.

Key Points: 
  • This is happening at the same time as they struggle to find laboratory real estate as well as finding and retaining skilled lab staff.
  • This convergence is leading to organisations rethinking their tooling, data infrastructure and ability to experiment at scale.
  • Moller Holding, added:
    ““We are delighted to partner with Automata, an emerging leader in modernizing and automating the global life science industry.
  • Automata’s solutions help increase throughput, lower cost, and accelerate innovation allowing its customers to focus on pushing further into cutting edge medical and life science research.”

Global Radiography Systems Market Report 2022: Increasing Use of Ai-Enabled Diagnostic Equipment for Rapid Diagnosis and Predictive Analysis Bolsters Growth

Retrieved on: 
Wednesday, April 5, 2023
CT, GE HealthCare, Prevalence, Diabetes, Osteoporosis, Hospital, COVID-19, Cardiovascular disease, Cancer, Risk, Product type, Blood, MRI, Tuberculosis, Cardiology, Lower respiratory tract infection, Geography, Conditional sentence, Growth, Fluid mechanics, Hospital Insurance and Diagnostic Services Act, Mammography, Pneumonia, Breast cancer, Medical imaging, Pet industry, Unilab, Fujifilm

By Application: The Cardiology segment held the largest market share of the Global Radiography systems Market in 2021, primarily due to the surge in the prevalence of cardiovascular disease.

Key Points: 
  • By Application: The Cardiology segment held the largest market share of the Global Radiography systems Market in 2021, primarily due to the surge in the prevalence of cardiovascular disease.
  • By End User: The Hospitals and Clinics segment accounted for the majority share of the Global Radiography systems Market in 2021.
  • By Geography: North America accounted for the largest market share in the global radiography systems market in 2021.
  • The region's developed healthcare and hospital infrastructure is also a major factor behind the expansion of radiography systems.

Spain Diagnostic Labs Markets, Competition, Forecast & Opportunities, 2017-2022 & 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Health, Biotechnology, CDB, Radiology, Pathology, Walk In, Medical device, Diagnosis, Hospital, Point-of-care testing, Research, Vertically transmitted infection, Growth, Prevalence, Medical imaging, Semiconductor, Unilab

Spain diagnostic labs market is anticipated to witness a growth of steady CAGR in the forecast period, 2023-2027

Key Points: 
  • Spain diagnostic labs market is anticipated to witness a growth of steady CAGR in the forecast period, 2023-2027
    Factors such as the increased prevalence of infectious and chronic diseases and the booming healthcare industry are driving the demand for the Spain diagnostic labs market.
  • The Spain diagnostic labs market is segmented into provider type, test type, end user, regional distribution, and competitive landscape.
  • To estimate and forecast the market size of Spain diagnostic labs market from 2023 to 2027 and growth rate until 2027.
  • To classify and forecast the Spain diagnostic labs market based on provider type, test type, end user, region, and company.

Unilabs and Ambry Sign Agreement to Enhance Genetic Testing Services for Biopharma Companies in Europe, Latin America and the Middle East

Retrieved on: 
Thursday, January 26, 2023
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Physician, Radiology, Forest Law Enforcement and Governance Program, Drug development, CARE, Patient, Education, Risk, Partnership, Genomics, Genetic testing, Multimedia, Chief medical informatics officer, Hospital Insurance and Diagnostic Services Act, Medical imaging, Pharmaceutical industry, Unilab, Ambry

Unilabs , a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx , have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.

Key Points: 
  • Unilabs , a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx , have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.
  • View the full release here: https://www.businesswire.com/news/home/20230126005123/en/
    Ambry will use Unilabs’ genomic lab services and variant interpretation capabilities in Europe, Latin America and the Middle East – regions where Ambry does not have a physical presence.
  • Unilabs will also provide genetic evaluation and patient cohort recruitment for clinical trials and patient identification and stratification for targeted treatments.
  • “Together with our industry-leading clinical laboratory, radiology and digital pathology services, we provide access to a test menu of more than 4,000 genetic tests.

Global Radiography Systems Market Analysis Report 2022: A $40 Billion Industry by 2028 - Size, Segments, Outlook, and Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Health, Medical Devices, Technology, Health Technology, Other Technology, Other Health, Hardware, Product type, Joint, Cardiovascular disease, Swelling, Hospital, HRCT, Infection, Hospital Insurance and Diagnostic Services Act, COVID-19, Shimadzu, GE Healthcare, Agfa-Gevaert, Conditional sentence, Pregnancy, CT, Esaote, Osteoarthritis, Diagnosis, Patient, Prevalence, Diabetes, CT scan, Cancer, Canon Medical Systems Corporation, MRI, Spinal cord injury, Mammography, Carestream Health, General Electric Company, Network tomography, Pharmaceutical industry, Medical imaging, Unilab, Fujifilm

The "Global Radiography Systems Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Type, Application, End User and Regions" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Radiography Systems Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Type, Application, End User and Regions" report has been added to ResearchAndMarkets.com's offering.
  • According to this analysis, the Global Radiography Systems Market was valued at ~US$ 25 billion in 2017, it is estimated to be ~US$ 30 billion in 2022 and is expected to grow at a ~5% CAGR during 2022 to 2028, with market size of ~US$ 40 billion in 2028.
  • Increasing use of AI-enabled diagnostic equipment for rapid diagnosis and predictive analysis, notably in developed countries is one of the major contributing factors to the rising demand for radiography systems.
  • The ongoing COVID-19 pandemic has adversely affected the global radiography systems market in 2020, primarily due to a decline in patient visits to hospitals and clinics.

Anil Srivastava, chief executive officer, leaves Leclanché SA; Board announces management succession and reorganisation

Retrieved on: 
Monday, October 31, 2022
Rhea, SIX Swiss Exchange, Panasonic, JCB, Foglia, SICAV, SA, Leadership, View, Gothenburg School of Business, Economics and Law, Shareholder Meeting, Multimedia, Berkshire Hathaway, EQUITY, Economics, Libera Università Internazionale degli Studi Sociali Guido Carli, MAN, AM, Solution, CEO, Business, Heart, Trust, Blanc, Terminology, Industry, Caterpillar, Chief executive officer, Commercial vehicle, Systems engineering, New Board, Electricity, Volvo, Company, Motor vehicle, Commercial, Engineering, Diagnosis, Fair market value, Cell, Strategic planning, Growth, Phil, CFO, Procter & Gamble, Energizer, Management, Electric battery, Online shopping, Unilab, VARTA, Duracell

Following the appointment of the new board of directors on 30thSeptember 2022, an internal reorganisation of the management was initiated, together with Anil Srivastava, CEO of Leclanch SA.

Key Points: 
  • Following the appointment of the new board of directors on 30thSeptember 2022, an internal reorganisation of the management was initiated, together with Anil Srivastava, CEO of Leclanch SA.
  • As of today, Leclanch group will be managed by Pierre Blanc as Group CEO and by Phil Broad as CEO of Leclanch E-Mobility.
  • They will simultaneously join the executive committee of Leclanch SA with the following roles and functions:
    Phil Broad: CEO of Leclanch e-Mobility SA and chief sales & development officer of Leclanch SA.
  • Philip (Phil) Broad joined Leclanch in 2018 and was appointed executive vice president of e-Mobility Solutions in March 2019.

Unilabs Selects Proscia's AI For Skin Pathology

Retrieved on: 
Wednesday, September 14, 2022
H&E, Workflow, Marie Cassidy, Efficiency, Partnership, Melanoma, Patient, CEO, Technology, Pathology, Artificial intelligence, Skin cancer, Research, AI, Hospital Insurance and Diagnostic Services Act, Medical imaging, Pharmaceutical industry, Unilab

GENEVA and PHILADELPHIA, Sept. 14, 2022 /PRNewswire/ -- Unilabs, a leading diagnostic services provider, and Proscia®, a leading provider of digital and computational pathology solutions, today announced that the diagnostic group has chosen Proscia's DermAI®* to advance its aspiration of becoming the most digitally-driven diagnostic group – enabling better decisions for a healthier tomorrow. The artificial intelligence (AI)-enabled technology will first be deployed in Sweden and then rolled out across other countries where Unilabs serves patients.

Key Points: 
  • The artificial intelligence (AI)-enabled technology will first be deployed in Sweden and then rolled out across other countries where Unilabs serves patients.
  • "The era of computational pathology is here," said Dr Christian Rebhan, Chief Medical and Operations Officer at Unilabs.
  • "We are designing our diagnostic processes around AI because getting better, faster results to our patients can help to improve outcomes.
  • Unilabs and Proscia established a strategic partnership in March 2021 to study the potential impact of DermAI on the laboratory's high-throughput pathology operations.

Unilabs Sweden Launches Subtle Medical's AI-powered Imaging Technology to Further Bolstering Patient Care

Retrieved on: 
Wednesday, July 6, 2022
Efficiency, Acquisition, Patient, Intelligence, Radiology, Unilab, Partnership, Technology, ECR, Software, Symposia, Hospital Insurance and Diagnostic Services Act, Time, RSVP, MRI, Medical imaging, Medical device

The solution, which will first be rolled out in Sweden, will boost Unilabs' MRI programme to provide industry-leading productivity and an even more superior patient experience.

Key Points: 
  • The solution, which will first be rolled out in Sweden, will boost Unilabs' MRI programme to provide industry-leading productivity and an even more superior patient experience.
  • "Unilabs is dedicated to investing in healthcare innovation for the benefit of all of our patients.
  • "We could not be more pleased that Unilabs has adopted SubtleMR," said Josh Gurewitz, Chief Commercial Officer for Subtle Medical.
  • "Our unique technology not only supports a better patient experience from less time in the imaging suite but also increases operational workflow efficiencies that allow Unilabs to boost their already efficient imaging programme.

Danish CleanTech ZeroNorth Raises Over $50 Million Series B Round to Help Decarbonise Shipping

Retrieved on: 
Thursday, June 2, 2022
Finance, Professional Services, Other Technology, Technology, Software, New Center, Detroit, Agriculture, Food, Animal, Software, CEO, News, Climate, Growth, Venture round, PSG, Farmer, Technology, Industry, Cargill, CO2, Software as a service, Climate change, Maersk Drilling, Security (finance), Renewable energy, Maersk, Unilab

Technology company ZeroNorth has today announced it has raised over $50 million in investment during its recently concluded Series B investment round.

Key Points: 
  • Technology company ZeroNorth has today announced it has raised over $50 million in investment during its recently concluded Series B investment round.
  • The news means that ZeroNorth now has a trio of partners that will support the companys ambitious plans for continued growth.
  • As a demonstration of this impact, ZeroNorth is on course to help cut CO2 emissions by over half a million metric tonnes in 2022, up from 218,000 tonnes in 2021.
  • Commenting on the announcement, Sren Meyer, CEO of ZeroNorth, said: We are delighted to welcome PSG Equity as a new investor in ZeroNorth.

Proscia Introduces AI-Powered Quality Control to Accelerate Data-Driven Drug Development

Retrieved on: 
Tuesday, May 17, 2022
Technology, Research, Software, Biotechnology, Health, Pharmaceutical, Data Management, Science, Oncology, Cloud, Digital pathology, Disease, Johns Hopkins School of Medicine, Research, AI, Pathology, Multimedia, Solution, List of life sciences, Automation, Sell Control for Life's Speed, University Medical Center, Melanoma, H&E, COVID-19, Bristol Myers Squibb, University of California, FDA, Efficiency, Pressure, Artifact, University, Technology, Organization, Adoption, Blurry, Charles River Laboratories, Intelligence, University Medical Center Utrecht, Cancer, Diagnosis, Laboratory, Data management, Medical device, Medical imaging, Pharmaceutical industry, Unilab

Proscia , a leader in digital and computational pathology solutions, has introduced an automated quality control application that leverages artificial intelligence to improve quality and efficiency in data-driven drug development.

Key Points: 
  • Proscia , a leader in digital and computational pathology solutions, has introduced an automated quality control application that leverages artificial intelligence to improve quality and efficiency in data-driven drug development.
  • In launching automated quality control, Proscia is delivering on digital pathologys first suite of process automation solutions, streamlining manual, repetitive tasks with AI.
  • View the full release here: https://www.businesswire.com/news/home/20220517005410/en/
    Blurry, unreadable regions of an H&E stained slide image are detected and highlighted with Proscia's AI-powered automated quality control.
  • The launch of automated quality control marks the next milestone in Proscias journey to accelerate the adoption of AI in research and diagnostic pathology.